These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Minami Y; Ueshima K; Haji S Oncology; 2007; 72 Suppl 1():98-103. PubMed ID: 18087189 [TBL] [Abstract][Full Text] [Related]
26. [Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma]. Chen MS; Zhang YJ; Li JQ; Liang HH; Zhang YQ; Zheng Y Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):623-5. PubMed ID: 16438875 [TBL] [Abstract][Full Text] [Related]
27. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Fuke H; Sugimoto K; Shiraki K; Tanaka J; Beppu T; Yoneda K; Yamamoto N; Ito K; Takaki H; Nakatsuka A; Yamakado K; Takeda K; Takei Y Aliment Pharmacol Ther; 2008 Jun; 27(12):1253-60. PubMed ID: 18221404 [TBL] [Abstract][Full Text] [Related]
28. [Radiofrequency ablation of malignant liver tumors: use of a volumetric necrosis-tumor ratio for local control]. Kühl H; Stattaus J; Kühl B; Boes T; Antoch G; Frilling A; Forsting M Rofo; 2006 Dec; 178(12):1243-9. PubMed ID: 17136648 [TBL] [Abstract][Full Text] [Related]
29. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. Liao GS; Yu CY; Shih ML; Chan DC; Liu YC; Yu JC; Chen TW; Hsieh CB Eur J Surg Oncol; 2008 Jan; 34(1):61-6. PubMed ID: 17434711 [TBL] [Abstract][Full Text] [Related]
30. Radiofrequency ablation for the treatment of liver tumors in the caudate lobe. Seror O; Haddar D; N'Kontchou G; Ajavon Y; Trinchet JC; Beaugrand M; Sellier N J Vasc Interv Radiol; 2005 Jul; 16(7):981-90. PubMed ID: 16002506 [TBL] [Abstract][Full Text] [Related]
31. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: Short-term recurrences and survival. Yamakado K; Nakatsuka A; Akeboshi M; Shiraki K; Nakano T; Takeda K Oncol Rep; 2004 Jan; 11(1):105-9. PubMed ID: 14654911 [TBL] [Abstract][Full Text] [Related]
32. Intraoperative radiofrequency ablation with or without tumorectomy for hepatocellular carcinoma in locations difficult for a percutaneous approach. Kim HO; Kim SK; Son BH; Yoo CH; Hong HP; Cho YK; Kim BI Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):591-6. PubMed ID: 20007075 [TBL] [Abstract][Full Text] [Related]
33. Radiofrequency ablation of small lung metastases by a single application of a 2-cm expandable electrode: determination of favorable responders. Sakurai J; Hiraki T; Mimura H; Gobara H; Fujiwara H; Tajiri N; Sano Y; Kanazawa S J Vasc Interv Radiol; 2010 Feb; 21(2):231-6. PubMed ID: 20022763 [TBL] [Abstract][Full Text] [Related]
34. Radiofrequency Ablation of Lung Tumors Using a Multitined Expandable Electrode: Impact of the Electrode Array Diameter on Local Tumor Progression. Ihara H; Gobara H; Hiraki T; Mitsuhashi T; Iguchi T; Fujiwara H; Matsui Y; Soh J; Toyooka S; Kanazawa S J Vasc Interv Radiol; 2016 Jan; 27(1):87-95. PubMed ID: 26321016 [TBL] [Abstract][Full Text] [Related]
35. Radiofrequency ablation (RFA) of pulmonary metastases: technical success vs. actual benefit. Detterbeck FC Ann Surg Oncol; 2010 Apr; 17(4):1214; author reply 1215. PubMed ID: 20336818 [No Abstract] [Full Text] [Related]
37. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Lin YM; Taiji R; Calandri M; Odisio BC Curr Oncol Rep; 2021 Apr; 23(6):67. PubMed ID: 33855606 [TBL] [Abstract][Full Text] [Related]
38. [Secondary cancer of the lung with balloon release: a case of recovery following ablation of primary renal cancer, maintained for 2 years]. LAGEZE P; DURAND L; TAINE B J Med Lyon; 1958 Oct; 39(930):821-30. PubMed ID: 13598979 [No Abstract] [Full Text] [Related]
39. The PulMiCC Trial Provides Control Data for Colorectal Lung Metastases Amenable to Local Treatments. Williams NR; Milošević M; Treasure T; Macbeth F Cardiovasc Intervent Radiol; 2021 Apr; 44(4):654-655. PubMed ID: 33205294 [No Abstract] [Full Text] [Related]
40. Reply to: The PulMiCC Trial Provides Control Data for Colorectal Lung Metastases Amenable to Local Treatments. Bhartia B; Zhong J; Chaudhuri N; Milton R; Smith J; Lenton J; Wah TM Cardiovasc Intervent Radiol; 2021 Apr; 44(4):656-657. PubMed ID: 33501521 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]